Download the Free Prime PubMed App to your smartphone or tablet.

Available for iPhone or iPad:

Unbound PubMed app for iOS iPhone iPadAlso Available:
Unbound MEDLINE
Unbound PubMed app for Android

Available for Mac and Windows Desktops and laptops:

Unbound PubMed app for Windows
(rotigotine)
544 results
  • Pain in Parkinson's disease: new concepts in pathogenesis and treatment. [Journal Article]
    Curr Opin Neurol 2019; 32(4):579-588Rukavina K, Leta V, … Ray Chaudhuri K
  • CONCLUSIONS: Pain in Parkinson's disease is not simply a consequence of motor complainants. The management of Parkinson's disease-related pain implicates maintenance of stable levels of dopaminergic drugs. Nondopaminergic pharmacological therapies (prolonged-release oxycodone/naloxone, duloxetine, BTX) and nonpharmacological interventions (DBS, physiotherapie) may also be beneficial in treatment of Parkinson's disease pain.
  • Rotigotine Transdermal Patch: A Review in Parkinson's Disease. [Journal Article]
    CNS Drugs 2019; 33(7):707-718Frampton JE
  • Rotigotine (Neupro®), a non-ergolinic dopamine agonist (DA), is administered once daily via a transdermal patch (TP) that delivers the drug over a 24-h period. In the EU, the rotigotine TP is approved as monotherapy for the treatment of early Parkinson's disease (PD) and as combination therapy with levodopa throughout the course of the disease. It is also approved for the treatment of PD in numer…
  • D3 receptor agonist efficacy in restless legs syndrome. [Journal Article]
    Adv Pharmacol 2019; 84:21-35Casoni F, Galbiati A, Ferini-Strambi L
  • Restless Legs Syndrome/Willis Ekbom Disease (RLS/WED) is a sleep related movement disorder characterized by an irresistible urge to move the limbs frequently associated with uncomfortable sensations that usually begin or worsen during inactivity and may be relieved by movement. The pathophysiology of the disorder involves several biological system; in particular, dopaminergic pathway and iron phy…
  • Old Drugs, New Delivery Systems in Parkinson's Disease. [Review]
    Drugs Aging 2019; 36(9):807-821Gupta HV, Lyons KE, Pahwa R
  • Levodopa is the mainstay of treatment in Parkinson's disease (PD). As the disease progresses, variations in plasma levodopa levels lead to motor fluctuations. The common reasons behind variations in the plasma levels include delayed gastric emptying, small intestinal bacterial overgrowth, protein interaction with levodopa absorption, and limited oral bioavailability of levodopa. Efforts to find n…
  • Quantitative Comparison of the Efficacies of 5 First-Line Drugs for Primary Restless Leg Syndrome. [Journal Article]
    J Clin Pharmacol 2019; 59(9):1177-1187Zhang N, Li Y, … Zheng Q
  • Comparative analyses of the efficacies of dopaminergic agonists (pramipexole, ropinirole, and rotigotine patch) and α-2-δ ligands (gabapentin enacarbil and pregabalin) for treatment of primary restless leg syndrome (RLS) are lacking because of the few head-to-head clinical trials. A model-based meta-analysis approach was employed to quantitatively compare the efficacies of these 5 first-line RLS …
New Search Next